🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

173 results for “inhibitor” Clear

  1. Study of Repotrectinib and CYP450 probe Cocktail in Patients with locally advanced or Metastatic Tyrosine Kinase Inhibitors (TKI)-Pretreated ROS1-Positive Non-small Cell Lung Cancer (NSCLC)

    Bristol-Myers Squibb Australia Pty Ltd

    Non-small Cell Lung Cancer (NSCLC)

    phase 1 other active

    1 trial

  2. VEGF inhibitor PTC299

    PTC THERAPEUTICS, INC.

    Brain and Central Nervous System Tumors

    phase 1 small molecule completed

    1 trial

  3. sphingosine kinase-2 inhibitor ABC294640

    Apogee Therapeutics

    Pancreatic Cancer

    phase 1 small molecule completed

    1 trial

  4. AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , CEFEPIME , CEFOTAXIME, SPIRAMYCIN , PIPERACILLIN AND BETA-LACTAMASE INHIBITOR

    Pari Pharma GmbH

    EA-COPD (with mechanical ventilation, invasive or non-invasive, or high-flow nasal oxygen therapy).

    approved small molecule active

    1 trial

  5. AMPICILLIN , AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , OFLOXACIN , MOXIFLOXACIN , AZITHROMYCIN , LEVOFLOXACIN , AMOXICILLIN , PRISTINAMYCIN , ERYTHROMYCIN , CIPROFLOXACIN , CLARITHROMYCIN

    Pari Pharma GmbH

    Community acquired pneumonia (CAP)

    approved small molecule active

    1 trial

  6. ARALAST Alpha1-Proteinase Inhibitor

    Takeda

    Alpha1-antitrypsin Deficiency

    approved small molecule terminated

    1 trial

  7. Alpha1-Proteinase Inhibitor

    Takeda

    Alpha 1-Antitrypsin Deficiency

    approved mab completed

    1 trial

  8. Alpha1-proteinase inhibitor

    Takeda

    Alpha1-antitrypsin Deficiency

    approved mab completed

    1 trial

  9. C1 inhibitor (human) [C1 INH]

    Takeda

    Hereditary Angioedema

    approved mab completed

    1 trial

  10. Dapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy

    The University of Hong Kong

    Fontan

    approved small molecule active

    1 trial

  11. Feiba

    Takeda

    Hemophilia A With Inhibitor

    approved small molecule active

    1 trial

  12. JAK Inhibitor

    The First People's Hospital of Lianyungang

    Dermatomyositis, Adult Type

    approved small molecule active

    1 trial

  13. MEROPENEM AND VABORBACTAM , LINEZOLID , TEDIZOLID , SULFAMETHOXAZOLE AND TRIMETHOPRIM , -, CEFTAZIDIME AND BETA-LACTAMASE INHIBITOR , -, DAPTOMYCIN , -, COLISTIN , -, METRONIDAZOLE , AMIKACIN , IMIPENEM, CILASTATIN AND RELEBACTAM

    Pari Pharma GmbH

    Pyogenic liver abscess

    approved small molecule active

    1 trial

  14. Proton Pump Inhibitors

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Upper Gastrointestinal Hemorrhage

    approved small molecule active

    1 trial

  15. SGLT2 inhibitor

    The First People's Hospital of Lianyungang

    Type2 Diabetes

    approved small molecule active

    1 trial

  16. SGLT2 inhibitor (Empagliflozin 25 MG)

    Hospital Authority, Hong Kong

    Type2 Diabetes

    approved small molecule active

    1 trial

  17. Selective serotonin reuptake inhibitor (SSRI)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Anxiety Depression

    approved small molecule active

    1 trial

  18. rFVIIIFc

    Sanofi Pasteur

    Hemophilia A With Inhibitors

    approved mab completed

    1 trial

  19. Aromatase inhibitor (litrezole) plus uFSH arm

    Universal Integrated

    Polycystic Ovary Syndrome

    small molecule active

    1 trial

  20. FGFR Inhibitor, IDH1 Inhibitor, HER2 Inhibitor, PARP Inhibitor, BRAF Inhibitor, MEK Inhibitor, ICIs, EGFR-TKIs, NTRK-TKI, and et. al.

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Biliary Tract Neoplasms

    small molecule active

    1 trial

  21. JAK Inhibitor

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Antisynthetase Syndrome

    small molecule active

    1 trial

  22. PCSK9 inhibitor

    The First People's Hospital of Lianyungang

    Intracranial Artery Stenosis

    small molecule active

    1 trial

  23. PCSK9 inhibitor (PCSK9i)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Coronary Artery Disease

    small molecule active

    1 trial

  24. Ruxolitinib+Calcineurin inhibitor+Methotrexate

    The First People's Hospital of Lianyungang

    Graft Versus Host Disease

    small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources